Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Phase 2 study of dara/thal/dex in relapsed and/or refractory MM finds median PFS 16 months (9.4 if thal/len/pom refractory), ORR 82% (64% VGPR or better, 25% CR or better, 13% sCR), median DOR 19 mos, median OS 32.5 mos.”
Title: A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
Authors: Chandramouli Nagarajan, Wei-Ying Jen, Melissa Ooi, Sanjay De Mel, Cinnie Soekojo, Sung Soo Yoon, Melinda Tan, Yunxin Chen, Xinhua Li, Yogesh Pokharkar, Shi Ning Tham, Nur Shahidah Binte Hashim, Neha Awasthi, Sarah M. Burkill, Brian Durie, Wee Joo Chng
You can read the Full Article in the Blood Cancer Journal.
More posts featuring Robert Orlowski.
